Keyif Betül, Yurtçu Engin, Başbuğ Alper, Yavuzcan Ali, Goynumer Fikret Gokhan
Department of Obstetrics and Gynecology, Faculty of Medicine, Duzce University, 81600 Duzce, Turkey.
Department of Obstetrics and Gynecology, Faculty of Medicine, Sağlık Bilimleri University, Ankara Bilkent City Hospital, 06800 Ankara, Turkey.
Metabolites. 2025 Mar 9;15(3):182. doi: 10.3390/metabo15030182.
: This study aims to investigate the potential role of vasorin as a novel biomarker in the pathogenesis of polycystic ovary syndrome (PCOS) by evaluating serum vasorin levels in women diagnosed with PCOS. : A prospective study was conducted at Düzce University Faculty of Medicine between March and July 2024, including 92 women with PCOS, diagnosed based on the 2003 Rotterdam criteria, and 68 age- and BMI-matched healthy controls. Serum vasorin levels were measured using an enzyme-linked immunosorbent assay (ELISA) and compared between the two groups. Additionally, correlations between vasorin levels and metabolic, inflammatory, and hormonal parameters were analyzed. : Women with PCOS had significantly lower serum vasorin levels (median: 0.70 pg/mL) compared to the control group (median: 2.36 pg/mL, < 0.001). No significant correlation was found between vasorin and metabolic or hormonal parameters in the PCOS group. However, a weak positive correlation with prolactin was observed in the control group (r = 0.264, = 0.030). Although vasorin is involved in inflammatory and oxidative-stress pathways, its association with insulin resistance and lipid metabolism remains unclear based on this study. Receiver Operating Characteristic (ROC) curve analysis demonstrated a high diagnostic performance for vasorin in distinguishing PCOS from healthy individuals (AUC = 0.918, < 0.001, 95% CI: 0.869-0.967). The optimal cutoff value for vasorin (1.285 pg/mL) yielded 92.6% sensitivity and 87.0% specificity. : These findings suggest that vasorin may serve as a promising biomarker for PCOS, potentially linking hormonal dysregulation, inflammatory responses, and ovarian dysfunction. However, further validation is required through longitudinal studies, multi-center cohorts, and mechanistic investigations. Additionally, comparative assessments with established biomarkers such as anti-Müllerian hormone (AMH) and androgen levels are warranted to determine vasorin's diagnostic and prognostic utility in clinical practice.
本研究旨在通过评估多囊卵巢综合征（PCOS）女性的血清血管生成素水平，探讨血管生成素作为一种新型生物标志物在PCOS发病机制中的潜在作用。
2024年3月至7月在杜兹大学医学院进行了一项前瞻性研究，纳入了92名根据2003年鹿特丹标准诊断为PCOS的女性，以及68名年龄和体重指数匹配的健康对照。使用酶联免疫吸附测定（ELISA）测量血清血管生成素水平，并在两组之间进行比较。此外，分析了血管生成素水平与代谢、炎症和激素参数之间的相关性。
与对照组（中位数：2.36 pg/mL，P<0.001）相比，PCOS女性的血清血管生成素水平显著降低（中位数：0.70 pg/mL）。在PCOS组中，未发现血管生成素与代谢或激素参数之间存在显著相关性。然而，在对照组中观察到与催乳素呈弱正相关（r = 0.264，P = 0.030）。尽管血管生成素参与炎症和氧化应激途径，但基于本研究，其与胰岛素抵抗和脂质代谢的关联仍不清楚。受试者工作特征（ROC）曲线分析表明，血管生成素在区分PCOS与健康个体方面具有较高的诊断性能（AUC = 0.918，P<0.001，95%CI：0.869 - 0.967）。血管生成素的最佳截断值（1.285 pg/mL）产生了92.6%的敏感性和87.0%的特异性。
这些发现表明，血管生成素可能是PCOS的一种有前景的生物标志物，可能将激素失调、炎症反应和卵巢功能障碍联系起来。然而，需要通过纵向研究、多中心队列研究和机制研究进行进一步验证。此外，有必要与抗苗勒管激素（AMH）和雄激素水平等已确立的生物标志物进行比较评估，以确定血管生成素在临床实践中的诊断和预后效用。
